News Releases

SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing rapid efficacy of MET409, a potent, systemic and

SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the appointment of Hubert C. Chen, M.D., as Chief Medical Officer, and Andrew Guggenhime as a director of

SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced dosing of the first subjects in a Phase 1 randomized, double-blind, placebo-controlled,

Proceeds will support clinical development of FXR program in NASH and GI diseases SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has

SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today presented data showing equivalent efficacy of M480, a potent oral non-bile acid farnesoid X receptor

SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2018 Global Healthcare

SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced two new key management appointments. Trisha M.

SAN DIEGO, March 7, 2018 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced that Ken Song, MD, President and CEO, will participate in two upcoming investor conferences. Dr. Song will give a corporate presentation and participate in a

SAN DIEGO, Dec. 7, 2017 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced it has closed a $22M Series B financing led by new investor New Enterprise Associates (NEA), along with participation from existing investors ARCH, Polaris,

SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD)